Premium
Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load
Author(s) -
Shata Mohamed Tarek M.,
Pfahler Wolfram,
Brotman Betsy,
Lee DongHun,
Tricoche Nancy,
Murthy Krishna,
Prince Alfred M.
Publication year - 2006
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1111/j.1600-0684.2006.00152.x
Subject(s) - virology , hbsag , lamivudine , viral load , modified vaccinia ankara , immunization , hepatitis b virus , dna vaccination , medicine , virus , hbcag , immunology , antigen , biology , vaccinia , recombinant dna , gene , biochemistry
Background We previously reported successful therapeutic immunization in a chimpanzee having a relatively low viral load, which was immunized with recombinant plasmid hepatitis B surface antigen (HBsAg) DNA and boosted with recombinant HBsAg encoding canarypox virus. In the present study, we attempted to confirm these findings in an animal with a high virus load. Methods and Results We tested three immunization strategies successively over a 3‐year period. In the first of these, we administered four monthly injections of DNA encoding HBsAg + PreS2 + hepatitis B core antigen (HBcAg) + DNA encoding interleukin (IL)‐12, (given 3 days later), and boosted with canarypox expressing all of the above HBV genes 6 months after initial immunization. No reduction in viral load was observed. In the second trial, we administered lamivudine for 8 weeks, and then began monthly DNA‐based immunization with plasmids expressing the above viral genes; however, viral loads rebounded 1 week after termination of lamivudine therapy. In a third trial, we continued lamivudine therapy for 30 weeks and immunized with vaccinia virus expressing the above viral genes 18 and 23 weeks after the start of lamivudine therapy. Again viral loads rebounded shortly after cessation of lamivudine treatment. Analysis of cell‐mediated immune responses, and their avidity, revealed that DNA‐based immunization produced the strongest enhancement of high avidity T‐cell responses, while recombinant vaccinia immunization during lamivudine therapy enhanced low avidity responses only. The strongest low and high avidity responses were directed to the middle surface antigen. Conclusions Three strategies for therapeutic immunization failed to control HBV viremia in a chronically infected chimpanzee with a high viral load.